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ABSTRACT 
 
Parkinson’s disease (PD) and Huntington’s disease (HD) are neurodegenerative disorders 
characterized by a progressive multi-systemic accumulation of misfolded proteins associated 
with neuronal dysfunction and neuronal loss. The rationale of this thesis is to examine, by 
means of the state of the art Positron emission tomography (PET) methodology combined 
with the use of high resolution MRI image molecular changes associated to the early stages of 
PD and HD.  PET is a molecular imaging technique that, due to recent advancements in terms 
of radioligand development and PET instrumentation, such as the high-resolution research 
tomograph (HRRT) and PET quantification, may contribute to examine in vivo the 
distribution and availability of different biochemical targets. The work included in the thesis 
can be subdivided into two projects.  
The first project is dedicated to PD and to the study of two relevant molecular targets 
(dopamine and serotonin transporters), examined respectively with the radioligands [18F]FE-
PE2I and [11C]MADAM. In paper I, it is shown that [18F]FE-PE2I represents a reliable 
imaging biomarker to study the dopamine transporter (DAT) in the striatum and in the 
substantia nigra in PD. In paper II, a validation of a new approach to examine the serotonin 
transporter protein in small brainstem structures is presented. In paper III, [18F]FE-PE2I was 
used to study the entire nigro-striatal dopaminergic system, including dopamine projections, 
in a larger group of PD patients. The study was able to show a prominent involvement of the 
dopamine transporter in the striatum, a relatively milder reduction of DAT in the substantia 
nigra and a relative preservation of the protein along the nigro-striatal projections.  
The second project is dedicated to the evaluation of Phosphodiesterase 10A as new molecular 
target for HD. This project includes two studies in which the radioligand [18F]MNI-659 has 
been used as radioligand for PDE10A and the D2/3 receptors radioligand [11C]raclopride that 
has been used as internal reference. In paper IV, it is shown that aging is associated with a 
considerable reduction of PDE10A. In Paper V, the same targets are examined in selected 
cohorts of HD subjects in pre-manifest and manifest stages. The study shows that PDE10A 
was preserved in early pre-manifest HD subjects and progressively decreased in late pre-
manifest and manifest HD stages.  
In conclusion the presented applications of new PET molecular imaging probes provided 
relevant information that contributes to measure early changes of molecular targets associated 
with the onset and progression of neuronal loss occurring in PD and HD.  
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1 INTRODUCTION 
 
1.1 MOVEMENT DISORDERS AND BASAL GANGLIA 
Movement disorders are a group of central nervous system’s syndromes characterized by an 
impairment of voluntary movements, abnormal muscle tone, involuntary movements and 
abnormal postures and postural reflexes. There are two main categories: hyperkinetic movement 
disorders characterized by an excess of involuntary movements and hypokinetic movement 
disorders in which a global reduction of movement is present.  
Movement disorders were traditionally related to dysfunction of the extra-pyramidal system 
which is composed by different central nervous system structures (basal ganglia, cerebellum, 
and different thalamic nuclei) and pathways (nigrostriatal, striato cortical) involved in the 
modulation and regulation of movement.     
Basal ganglia are the anatomical structures mostly involved in movement disorders. They are 
grey matter structures located medially and deeply in the encephalon, characterized by dense 
internuclear projections. Basal ganglia receive inputs from all cortical areas (sensory, motor, and 
associative) and produce a much lower number of outputs mainly back to the cortex and in 
minor extent to the brainstem and cerebellum (1,2). Five parallel and closed circuits have been 
proposed (motor, ocululomotor, dorsolateral prefrontal, lateral orbitofrontal and limbic). It is 
now generally agreed that these loops follow a functional and structural organization with 
subdivisions into sensorimotor, associative, and emotional functions (3). In this functional 
organization one of the major roles of basal ganglia appears to be in mediating automatic 
activities. 
Different brain structures compose the basal ganglia: 
a) The striatum that is composed by the caudate nucleus, the putamen and by the nucleus 
accumbens. The striatum represents the main input structure of the basal ganglia circuit.  
b) Globus pallidus pars interna (GPi) and externa (GPe). The pars interna is the main 
output structure of the basal ganglia circuit.    
c) The substantia nigra pars compacta (cell dense pigmented regions) and the pars 
reticulata (unpigmented). The main source of dopamine innervations is found in the 
substantia grigia pars compacta.  
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Connected to this functional core there are other associated nuclei   
d) Ventro-lateral nuclei of the thalamus. 
e) Subthalamic nuclei of Luys. 
Striatal GABAergic medium spiny neurons (MSNs) densely receive dopaminergic input from 
the substantia nigra and other input from cortical and thalamic projections. Those neurons 
integrates information from the substantia nigra and project to other connected interface nuclei 
and to the rest of the brain (2). GPi is the most important basal ganglia interface structure. It 
facilitates thalamic inhibition and consequently modulates the cortex using excitatory 
(glutamatergic) synaptic connections.  
Two major pathways are traditionally described between the striatum and the GPi and are part of 
the 3 functional systems described above (sensorimotor, associative and emotional) 
1. A direct pathway which is inhibitory and modulates directly  the substantia nigra pars 
reticulata and the subthalamic nucleus. 
2. An indirect pathway which is excitatory and modulates the GPi with a multisynaptic 
circuit that reaches the interface (GPi) through an intermediate connection with the GPe.   
The direct pathway provides a direct inhibition whereas the indirect pathway provides a thalamic 
excitation through disinhibition. Traditionally the direct pathway should promote the movement 
whilst the indirect pathway should reduce it (4). A molecular distinguishing feature of the two 
pathways is the differential expression of dopamine receptors. D1 dopamine receptors are 
selectively expressed in the direct pathway, whereas in the indirect pathway mostly D2 receptors 
are expressed. Despite the mentioned molecular and functional differentiation some preclinical 
data recently supported the idea that both intrastriatal connections (direct and indirect) work 
dynamically in concert depending on the form of the synaptic plasticity expressed with a given 
motor action (5). The classic schematic description of basal ganglia circuitries has contributed to 
characterize the role of dopamine in the modulation of different basal ganglia structures but it 
represents an oversimplification of the basal ganglia complexity (6).  
Nowadays, the close link between basal ganglia function and the control and modulation of 
motor functions have expanded to account a broad sets of non motor functions in which the 
basal ganglia are involved such as cognition, learning and behavior (7-9).  
The traditional description does not take into account the complexity that might be added if the 
contribution of other players is considered. For instance, other neurotransmitter systems are also 
involved in the regulation of the basal ganglia circuits (10-12). The striatum appears to be 
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functionally sub-compartmentalized in striosome and matrix with distinct neurochemical 
organization that have an impact on dopamine dynamics and striatal synaptic functions (13).The 
subthalamic nucleus is also an important supplementary input structure (cortico-subthalamic-
pallidal hyper-direct pathway) (14).  
The mentioned complexity is furthermore sustained by different patterns of electrophysiological 
activities in the different striatal nuclei (15). In particular synchronized neural oscillations in the 
beta and gamma frequency may contribute to regulate and optimize network functionalities and 
dopamine release. In PD for example, an excess of synchronization has been recently described 
(16).   
The traditional models might also contribute to the understanding of some aspects of the motor 
symptoms that occur in movement disorders but it becomes less complete when other important 
features of movement disorders are considered. In fact, so far, movement disorders have been 
traditionally associated to the dysfunction of the motor circuit of the basal ganglia. Hypokinetic 
features of movement disorders (i.e. bradykinesia in parkinsonism) have been explained by the 
progressively reduced dopamine stimulation. The decrease in dopaminergic input would 
generate a reduced inhibition of the indirect pathway and a decreased excitation of the direct 
pathway, resulting in a final increase of the thalamic inhibitory activity to the premotor and 
motor cortical areas. On the other hand, the predominant reduction of signaling in the indirect 
pathway has been linked to the reduced suppression of involuntary movements (chorea) that 
occurs in Huntington’s disease (4).  
The ground for the co-existence of hyperkinetic and hypokinetic features is still under 
investigation in some disorders such as in HD and advanced PD. Moreover, it has been 
considered “a paradox” the positive consequences that occurred after focal lesions in basal 
ganglia regions (i.e. thalamotomy, pallidotomy, subthalatomy) which have been performed with 
stereotaxic surgery (17,18). This might also be connected with the complexity, dynamic and 
integration of the signaling of basal ganglia with the rest of the brain.  
Future investigations might shed some light on the mentioned limitation of those models and 
may contribute to explain the clinical variability of motor, behavioral and cognitive symptoms 
observed in patients with movement disorders. 
PET molecular imaging represents a useful tool to evaluate and characterize the role of different 
molecular targets involved in the modulation of basal ganglia circuits.  
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1.2 POSITRON EMISSION TOMOGRAPHY 
Positron Emission tomography (PET) is an in vivo molecular imaging technique able to examine 
the distribution and concentrations of radiolabeled compounds binding to different molecular 
targets. Radiolabeled compounds are referred to as radioligands. In recent years ~ 400 targets 
have been evaluated and ~ 40 radioligands were developed and applied in vivo for PET studies 
of the human brain. For research or clinical purposes PET has been used to measure the blood 
flow, glucose metabolism, receptor density and enzyme activities. The basic principle of PET 
stands on the measurement of emitting annihilation photons that are generated from the decay of 
positron-emitting or isotopes (18F,11C,13N,15O). Positrons emitted in matter lose most of their 
kinetic energy until an interaction by annihilation with an electron of the surrounding matter (i.e. 
brain parenchyma) occurs. The annihilation produces a pair of photons (gamma rays) with a 
known energy (~ 511 KeV) and direction (180 º) that are detected and recorded simultaneously 
by scintillation crystals (the basic detector hardware of a PET system) for the entire duration of 
the PET acquisition (Figure 1).   
 
1.2.1 Image and data acquisition 
A dynamic PET study consists in a continuous measurement of the emitted radioactivity 
(coincidences) in a period of time that varies among different radioligands (commonly 60-90 
minutes). A PET radioligand is administered intravenously to the subjects and in this way enters 
into the circulation. From the venous blood stream the radioligand arrives to the heart chambers 
and then is distributed into the arterial circulation (Figure 1). After 10-15 seconds the 
radioligand arrives at the capillary bed where exchanges with the tissue begin to take place. A 
fraction of the radioligand is extracted from blood to the tissue and a fraction (depending of its 
reversible or irreversible behavior) leaves the tissue and returns into the main circulation. In the 
target tissue such as the brain, in this manner, the concentration of radioligand changes over time 
and the radioactivity is detected by measuring the number of events generated by the 
annihilation of positrons with electrons (Figure 1).  
The collected data are subdivided into frames of different durations that are physiologically 
coherent with the fate of the radioactivity in the specific target. At the end of the acquisition the 
detected information (the projections of the pair of photons) is reconstructed by dedicated 
algorithms in order to create 3D images for each time frame. 
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Figure 1. Image depicting the fate of a given radioligand after an intravenous injection. When the 
molecular target is reached the annihilation phenomena occurs and the pairs of photons are detected by 
the PET system.  
 
From the reconstructed dynamic sequence of images it is possible to derive time activity curves 
(TACs) that are usually extracted from a volume of interest (VOI) in the brain and by measuring 
the average volumetric concentration of radioactivity at each time frame (Figure 2).  
Another important requirement for a proper quantification of a radioligand is the measurement 
of radioactivity in the circulating blood (plasma and whole blood) and the generation of the so 
called arterial input function, that is the plasma concentration of unchanged radioligand over 
time. The input function is obtained by multiple samples of the arterial blood after cannulation 
of the radial artery, followed by separation of plasma from blood cells and measurement of the 
fraction of unchanged parent and metabolites with high-performance liquid chromatography. 
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Figure 2. Average standardized uptake value (SUV) time activity curves of a reversible radioligand 
 ([18F]MNI-659) in healthy controls subjects and in stage 1 HDGECs in a several regions of interest.  
 
1.2.2 Regional, template or voxel based analysis of PET Data 
When the 4D images are available, a set of VOIs are usually defined in order to extract the 
TACs that are used for the quantification of PET data. Different approaches are available for 
the definition of the VOIs and the choice is dependent on the specific study and on the target 
availability.  
The most common approach is the manual delineation of anatomical regions of interest upon 
MRI images. A prerequisite to manually define regions of interest (ROIs) is that the region 
should be clearly identifiable in the MRI images based on the presence of known anatomical 
landmarks. Some of the requisites are based upon a clear regional delimitation, a homogenous 
tissue composition (image intensity), and spatially heterogeneous MRI imaging properties. 
This procedure is time consuming and generally sensitive to biases due to differences between 
users.  
Another approach is to use automatic methods to define ROIs on MRI images. Different 
software packages for brain PET applications are now available and validated. These 
approaches utilize a priori anatomical information obtained from validated probabilistic brain 
atlases or anatomical parcellation strategies to assign anatomical labels to each MRI voxel. 
The set of preprocessing tools offered by the Freesurfer package 
(http://surfer.nmr.mgh.harvard.edu) represents a valid example of an automatic approach also 
used in two of the studies presented in this thesis (IV- IV). The technical details of pre-
processing of MRI images are described in prior publications (19,20).  
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For the generation of subcortical ROIs a section (volume based stream) of the Freesurfer 
pipeline is dedicated to the volumetric segmentation of the brain and to the labeling of tissue 
classes. The algorithm is based upon the existence of an atlas containing probabilistic 
information on the location of structures and on the subject specific measured value (21). This 
atlas and the relative spatial coordinates were obtained with a manually labeled training set of 
high-resolution MR images of 39 subjects. The advantage of this implementation is that it 
relies on a registration procedure that takes in account the anatomical variability including 
possible consequences of degeneration processes such as atrophy.  
 
1.2.3 Principles of quantification of radioligand binding 
The objective of quantification of radioligand binding is to generate physiologically relevant 
parameters able to describe and quantify radioactivity measurements of biological targets in the 
brain (receptor concentration, transporter protein availability, enzyme levels or activity and 
metabolic parameters) obtained with PET measurements. The biochemical fate of a radioligand 
and the relative tissue radioactivity concentration data are influenced by several factors such as 
plasma protein binding, permeability of the blood brain barrier, tissue blood flow, rate of the 
extraction of the tracer from the capillary, binding association and dissociation rates, non 
specific tissue binding and by the eventual presence of radioligand metabolites. In the current 
practice, mathematical models are employed to describe the precise relationship between the in 
vivo radioligand behavior and a set of parameters of interest in brain target tissues (22).  
In the studies presented in this thesis the kinetic of the radioligand is described by 
compartmental models that allow the estimation of exchange rates (rate constants) among tissue 
compartments (Figure 3). Those models assume that the injected radioligand will, at any given 
time, move and exist in one of the compartments, that each compartment is homogenous without 
concentration gradients and that the fractional rate of change of concentration in one 
compartment remains constant during the duration of the PET acquisition.  
From the estimation of the rate constants between compartments and from the known input 
function other macroparameters of interest are calculated such as the total distribution volume 
(VT) which is the ratio of the tissue concentration to the plasma concentration (input function) at 
equilibrium (22). Examples of compartmental models are presented in figure 3 below.  
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Figure 3. Compartmental models. Ca is the concentration of tracer in arterial plasma, C1, C2 are the tracer 
concentrations in compartments 1 and 2. K1, k2, k3 and k4 are the rate constants that define the rate of 
tracer exchange between compartments. A. One tissue compartment with irreversible uptake B. one tissue 
compartment with reversible tissue uptake C. Two tissue compartments with reversible uptake D. Two 
tissue compartments with irreversible uptake.   
 
Other approaches are also available if inside the brain parenchima there is a region (a reference 
region) with a negligible amount of specific binding. The general idea is that a regional TAC 
becomes the reference of the model in substitution of the arterial input function (23). When 
possible, this approach is preferable since there is no longer need of the arterial cannulation and 
this considerably reduces the subject’s discomfort during the study. Moreover,  graphical 
adaptations of reference tissue models are also available (i.e. non-invasive Logan graphical 
analysis) (24). Models based on linear graphical analysis are in some instances more efficient for 
some radioligands and also tend to reduce the computational requirement that becomes useful 
when the model is applied at voxel level (i.e. parametric images). Another advantage of this 
approach is that the derived parameter of interest is the non-displaceable binding potential 
(BPND) which is a more specific measure of target availability. BPND is defined as the ratio 
between the specifically bound radioligand to the non-displaceable binding at equilibrium.  
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1.2.4 Parametric images 
Another attractive approach to perform analysis of PET data is to perform parametric 
mapping. Parametric mapping approaches were established in order to estimate outcome 
measures of interest in each voxel that composes a PET image. As a result, 3D images with 
spatial maps of binding pattern expressed as outcome measure are generated. Different 
denoising strategies have been implemented and several attempts have been made to reduce 
the computational cost of measuring PET outcome measures at voxel level.  
An example of parametric images obtained in the Parkinson’s study with [18F]FE-PE2I is 
shown in figure 4. 
 
 
Figure 4. Representative DAT parametric images of [18F]FE-PE2I in a control subject (upper panel) 
and in an early PD patient (stage 1.5 Hoehn & Yahr) (lower panel). 
 
The method used at Karolinska Institutet PET Centre was developed in 2006 and it is based on 
a solution that uses a wavelet-based approach (25) The method also called wavelet-aided 
parametric imaging (WAPI) operates with the wavelet transformation to eliminate some 
known spatial frequencies (high frequencies) associated with the noise of a PET measurement. 
This approach have also been recently optimized to consider the PET system resolution and 
the reconstruction procedure (26). 
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1.3   MOLECULAR NEUROIMAGING IN MOVEMENT DISORDERS 
Primary forms of movement disorders are caused by a neurodegenerative etiology. In the human 
brain the macroscopic consequence of a neurodegenerative process is characterized by 
accumulation of protein aggregates, neuronal loss (with or without atrophy) and gliosis. 
Pathological alterations can be examined in vivo by means of structural imaging or in vitro by 
post mortem histological studies. Post mortem studies were particularly successful to precisely 
describe common features of different neurodegenerative processes, such as protein misfolding 
aggregation and accumulation (27). Pathological filamentous protein aggregates were 
progressively characterized and became the postmortem diagnostic golden standard: β-amyloid 
characteristic in Alzheimer’s disease (AD), hyperphosphorylated protein tau for Progressive 
Sopranuclear Palsy (PSP) and AD, α-synuclein for PD, Multiple System Atrophy (MSA) and 
dementia with Lewy bodies (DLB) and mutant huntingtin (mHTT) for Huntington’s disease. 
Different disease phenotypes might be explained by the consequences of distinctive functions of 
native (non-misfolded) proteins, different patterns of accumulation (regional distribution in the 
brain) or subcellular localization (intracellular or extracellular) of misfolded protein aggregates 
and finally by particular vulnerabilities of a different specific neuronal systems. 
The link between these pathological aggregates and neuronal apoptotic mechanisms has not 
been fully elucidated. Brain PET imaging represents a useful methodology to examine relevant 
in vivo characteristics, such as the distribution and availability of different biochemical targets 
in the diseased and healthy brain. In neurodegenerative disorders the general focus of PET 
imaging was traditionally focused on the study of dysfunctional molecular consequences related 
to different diseases. Several molecular targets have been explored with clinical PET studies 
such as different monoaminergic systems and relative receptors (dopamine, serotonin, 
cholinergic) and neurotransmitters (GABA, adenosine), regulatory intracellular enzymes 
(monoamine oxidase B, phosphodiesterase PDE4  and PDE10A), examination of cerebral blood 
flow and metabolism, neuroinflammation proteins (translocator protein) and last but not least in 
vivo protein accumulation patterns (beta-amyloid and tau). More recently, applications of 
molecular imaging techniques in vivo have focused on earlier phases of neurodegenerative 
processes which begin decades before a full phenotypic expression of the disease. Thus, 
dysfunctions of the molecular circuitries might be expected in preclinical and prodromal stages. 
With this perspective, one might also expect that the clinical and pharmacological management 
of patients affected by neurodegenerative disorders would benefit from the availability of 
reliable in vivo molecular biomarkers. 
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A possible application scenario could be that an imaging biomarker would be of great help to 
understand different clinical expressions or to support diagnostic workflows (i.e. differential 
diagnosis with atypical parkinsonisms, molecular stratification/enrichment of PD and HD 
individuals). Moreover, in an era in which the panel of disease-modifying therapies for 
neurodegenerative disorders is expanding (28-32) another potential application of early imaging 
biomarkers would be to monitor the disease progression and the efficacy of treatment when 
clinical outcomes may easily fail to produce relevant results (33,34). 
 
1.3.1 Parkinson’s Disease 
Parkinson’s disease (PD), at the time of the diagnosis, is clinically characterized by a 
progressive reduction of motor capacities with rigidity, hypokinesia, resting tremor, postural 
instability and an overall reduction of automatic movements. These typical motor signs are 
associated with a variegate set of non motor symptoms such as cognitive decline, autonomic 
dysfunctions, sleep related disorders and affective disorders. Non motor symptoms are becoming 
progressively more relevant for the medical and research communities because some of them 
initiate years before the clinical diagnosis (i.e. rapid eye movement [REM] sleep behavior 
disorders, constipation and olfactory dysfunctions) and may help to characterize a so called 
prodromal phase (35).  
From a neurobiological perspective, PD is now seen more as a group of disorders with a 
characteristic dopamine deficit due to degeneration of the dopaminergic nigro-striatal system. 
PD is characterized by a multiform accumulation of alpha-synuclein rich aggregates, different  
genetic susceptibilities and various lifestyle risk factors (i.e. smoking, coffee, urate and the 
composition of gut microbiome) (36-39). 
The genetic background of PD has recently been linked to mutations of different genes (i.e. 
alpha-synuclein, LRRK2, Parkin, PINK1, VPS35, DJ-1, ATP13A2, TMEM230) with 
autosomal dominant and recessive familial PD variants that account for 5-10% of cases (40). 
Moreover, in the majority of sporadic PD cases the disease may develop as a consequence of 
genetic susceptibility factors (polymorphisms in SNCA, LRRK2 and for heterozygous 
mutation in the GBA) (41,42). In some cases clinical correlations with Lewy pathology 
patterns have already been recognized (43) suggesting that the clinical heterogeneity might be 
sustained by a genetic substrate. The disease has a progressive course and patients usually 
experience a progressive decline of independence and a significant reduction of quality of life. 
The management of the disease is often challenging and becomes difficult in the advanced 
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stages of the disease. PD is the second most common neurodegenerative disorders with 
prevalence estimates that ranges between 100-300 per 100.000 (44-46). The burden for the 
society in term of care giving and finances is relevant if one considers that in Sweden there are 
approximately 20.000 people suffering from PD (47) and worldwide predictions anticipate that 
approximately 9 million people are going to be affected by 2030 (48).  
 
1.3.1.1 Neuropathology  
The neuropathology of PD is characterised by a multi-systemic progressive accumulation of 
misfolded oligomers and larger aggregates of α–synuclein (α-syn). The extensive distribution 
of aggregates called Lewy Bodies (LB) leads to a widespread neuronal and synaptic deficit 
responsible for the subsequent global and progressive derangement of the brain signaling in 
different portion of the nervous systems (central, peripheral and autonomic) (49). The variability 
of biochemical changes and the consequences of the described multi-system LB pathology 
might explain the clinical heterogeneity described in the previous section. According to 
extensive neuropathological descriptions of PD there are preferential propagation patterns (50, 
51). Braak et al described that LB deposition begins to accumulate in the anterior olfactory 
nucleus, dorsal motor nucleus of the vagus and in the myenteric neurons in the gastrointestinal 
nervous system (50). After the first occurrence, LB depositions tend to spread trans-synaptically 
among the nerve cells following a distribution subdivided in 6 stages. According to this model 
the pathological load throughout the brain progressively increases in a predictable fashion in a 
caudo-rostral direction reaching in stage 3-4 the mesenchephalon and the dopaminergic system 
in substantia nigra and the neocortex in the final stages. This staging system presents some 
caveats since, in many cases, it does not match the quality and progression of the clinical 
symptoms of PD patients and also the crucial involvement of the substantia nigra and the 
dopamine system (52,53). The dopaminergic neurons have been conventionally related to 
motor-symptoms in PD and are considered particularly vulnerable due to the complexity and 
size of the axonal arborization (54-56). Inclusions of α-syn have been traditionally described in 
a restricted compartment of the dopaminergic projections (substantia nigra) (57) but recently 
some authors have suggested a novel pathological hypothesis which claims that the primary 
neurodegenerative load is in the striatum at the pre-synaptic and axonal levels (58,59). In line 
with this hypothesis, different research groups (pre-clinical and clinical) have started  to 
observe and examine an early and larger degeneration of dopaminergic axonal terminals rather 
than substania nigra cell bodies in patients affected by PD (60,61). 
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1.3.1.2 Dopaminergic markers in PD 
The most evident molecular expression of PD is the progressive reduction of dopamine signaling 
due to the degeneration of dopaminergic striatal projections and substantia nigra cell bodies. The 
dopamine pathway begins in the liver where the precursor tyrosine is synthesized. Tyrosine is 
transported into the brain and to the dopamine neurons via diffusion carriers (Figure 5). Tyrosine 
is the precursor for biosynthesis of dihydroxyphenylalanine (DOPA) by the enzyme tyrosine 
hydroxylase. DOPA is subsequently converted into dopamine by aromatic aminoacid 
decarboxylase (AADC) in the dopaminergic neurons. Dopamine is transferred and kept into 
synaptic vesicles by type 2 vesicular monoamine transporters (VMAT2) until it is released into 
synaptic cleft to interact at a post-synaptic level with dopamine receptors.  
The fate of dopamine in the synapse is modulated with re-uptake mechanisms by the dopamine 
transporter protein (DAT) which is expressed in the plasma membrane. Dopamine can also be 
degraded by monoamine oxidase or cathecol O-methyltransferase. Many of the mentioned 
enzymes have been explored in vivo in clinical studies (Figure 5).   
 
 
Figure 5. Schematic representation of a dopamine synapse and the relative enzymes and functions (left 
panel). Representative DAT imaging and D2/3 imaging (right panel). 
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 [18F]Fluoro-L-dopa has been used as a biomarker for the dopaminergic functional integrity since 
it correlates with dopamine cell counts and levels (62) and reflects the activity of the AADC and 
VMAT2 (DOPA transformation, transport and storage). However, [18F]Fluorodopa uptake might 
underestimate the extent of the degenerative process in early PD for the presence of 
compensatory up-regulation (63, 64) and they might be influenced by the effects of the 
dopaminergic treatment (65).  
Targeting VMAT2 is another possibility already employed in clinical setting using the 
radioligand [11C]DTBZ and more recently an 18F-labeled version [18F]FP-DTBZ (66, 67). 
VMAT2 imaging has been considered a reliable measurement of dopaminergic integrity (DOPA 
vesicle storage and release), however the progressive dopamine deficit and therapies may 
influence the availability of VMAT2 as a consequence of up-regulation mechanisms (68, 69).  
DAT imaging (DATscan-SPECT/[123I]FP-CIT) is currently used clinically to support or reject 
the diagnosis of parkinsonism associated with striatal dopaminergic deficit and for the 
differential diagnosis with other conditions such as essential tremor, drug-induced/iatrogenic 
parkinsonism (70-73). Moreover, DATscan imaging enables the identification of another 
category of patients with parkinsonian-like symptoms without evidence of dopamine depletion 
in the striatum that are defined as SWEDD (scan without evidence of dopamine deficiency) 
which have recently generated interesting discussion in the field (74-76).  Several PET 
radioligands have been used to measure the availability of DAT: [11C]β-CFT, [18F]-FP-CIT, 
[11C]PE2I, [11C]RTI-32 and [11C]methylphenidate among others (77). Although the binding of 
these radioligands to DAT in PD patients might be influenced by the reduced levels of 
endogeneous dopamine, DAT binding estimates obtained so far in the striatum with the 
different probes offer a useful marker of the dopaminergic function impairment.  
All pre-synaptic markers (Fluorodopa, VMAT2 and DAT) have been found to decrease with the 
progression of the disease (78,79). In the early stages of the disease (Mild/stage Hoehn &Yahr 
1) the controlateral (opposite to the most affected clinical side) and posterior part of the putamen 
is the most involved with a reduction estimated to 45-70 % compared to healthy controls 
(67,68,78,80). Moreover, longitudinal PET studies in different PD cohorts have been able to 
show that the yearly decline of presynaptic dopaminergic markers in PD pathology is 
approximately 6-10 % (81-84).  
This thesis proposes as presynaptic imaging marker in PD and specifically has the objective to 
validate a DAT selective radioligand, [18F]FE-PE2I, that has been developed to image the DAT 
in the striatum and in the substantia nigra (85,86). Dopamine D2/3 receptors have also been 
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examined as post-synaptic markers of the dopaminergic system. Studies employing [11C] 
raclopride to measure D2/3 receptor availabilities have been successfully employed to study post-
synaptic differences between PD and the atypical parkinsonisms such as MSA and PSP. 
Reduced levels of post-synaptic receptors have been found in MSA and PSP compared to PD 
(87,88). Furthermore PD [11C]raclopride imaging have shown an interesting up-regulation of 
D2/3 receptors in the putamen in early PD drug naïve patients (89) and also in asymptomatic 
carriers of the Parkin gene mutation (90).  
 
1.3.1.3 Imaging serotoninergic transporter in PD 
The involvement of another monoaminergic system (i.e. serotonin) has been also hypothesized 
in light of the early involvement of the brainstem in the ascending neurodegeneration pattern 
described by the Braak staging system and in relation to some of the PD non-motor symptoms 
such as anxiety and depression (91). Supporting this hypothesis different pre-clinical, post-
mortem and clinical studies have shown the implication of serotonin system in PD. A seminal 
post-mortem immuno-histochemistry study strongly suggested an involvement of the different 
serotonin containing nuclei of the raphe in the brainstem (dorsal, medial and caudal) in PD 
patients (92). Another post-mortem study has demonstrated that both the neurotransmitter 
serotonin (5-HT) and its transporter (5-HTT) were reduced by 30 to 66%, with a preferential 
involvement of the caudate, compared to the putamen (93). Moreover, studies with PD animal 
models were able to describe that in presence of a dopaminergic dysfunction, the conversion of 
L-dopa to dopamine might be carried out by serotoninergic projections innervating the striatum 
(94). PET studies in PD have shown approximately a 30% decrease of 5-HTT availability in the 
subcortical and cortical areas (95, 96). More recently, higher 5-HTT availability in the dorsal 
raphe nuclei and limbic regions has also been found in PD patients with higher scores of 
depression (97, 98). These studies suggest that 5-HTT availability is already decreased in early 
PD patients, it is inversely related to disease stage (95) and positively related to scores of 
depression (97-99). Of interest is that the serotonin system seems to be involved in the 
pathophysiology of levodopa induced dyskinesia.  
The capability to evaluate serotoninergic targets in the different raphe nuclei has so far been 
challenged by the limited resolution of the PET system for such small brainstem structures. In 
this thesis, high-resolution PET imaging and a specific methodology to measure the 5-HT 
availability in the different nuclei of the brainstem have been used. The method developed can 
be used to examine the 5-HTT in the brainstem of PD patients. 
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1.3.2 Huntington’s disease 
Huntington’s disease is a genetically determined neurodegenerative disorder characterized by a 
highly variable and complex clinical phenotype consisting of movement disorder, neuro-
psychiatric impairments and cognitive deficits. Motor deficits are characterized by choreic 
movements, dystonia, parkinsonism, oculomotor dysfunctions, gait and balance disturbances, 
dysarthria and dysphagia. Cognitive symptoms encompass deficits in the executive dysfunction 
(concentration, attention, multi-tasking), lack of motivation and insight, reduction of problem 
solving and social cognition. Psychiatric problems include depression, anxiety, obsessive-
compulsive disorders, irritability, disinhibition, delusions, apathy and suicidality (100). HD 
belongs to the family of expanded CAG repeat disorders and is considered a progressive 
neurodegenerative disorder. The gene responsible for HD (IT15) was identified in 1993 (101, 
102). It is also defined as the huntingtin gene for the protein product that is coded by the gene. 
Different studies showed prevalence estimates of 5-10 patients per 100.000 in Europe, the two 
Americas and Australia and lower estimates in Finland and Asia (103, 104). Prevalence 
estimates are likely to be underestimated worldwide. The disease becomes clearly evident 
between 30 and 55 years. The age of onset is predictable but also influenced by other genes 
beside the HD gene and by environmental factors (105-107).  The availability of genetic tests 
made it possible to identify HD gene expansion carriers (HDGECs) before their evident clinical 
onset. The disease can thus be described in two different periods: the “pre-manifest” and the 
“manifest” period. When it is “manifest” the progression is inevitable and quite rapid (15-20 
years) even if the natural history may vary (108). The dysfunctions associated with the presence 
of mutant huntingtin (mHTT) are of complex nature and not yet fully understood. The molecular 
pathogenicity of mHTT seems to be connected to a typical conformational change and to its 
tendency to form insoluble aggregates in different neural cells. The specific cellular mechanisms 
involved in the neurodegenerative process are not yet fully understood, but a toxic gain of 
function is suspected (109, 110).  From a research and translational perspective, HD represents a 
unique suitable human model of neurodegeneration, since it is by nature monogenic, and it is 
associated with a long prodromal phase with a well characterized clinical evolution. 
 
1.3.2.1 Neuropathology 
The variability and richness of clinical signs in different domains are the consequence of a broad 
deranged signaling mainly linked to the loss of functions and degeneration of the cortico-striatal 
connections, the toxic gain of function of mHTT and to a toxic accumulation of protein 
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aggregates. As with other neurodegenerative diseases, the pathological process in HD begins 
several years before the evident clinical manifestation. MSNs in the striatum have been 
traditionally considered the main target of degeneration occurring in HD. The traditional 
neuropathological grading system was developed according to the neurodegenerative 
pathological (gross and microscopic level) temporal patterns found in the striatum. This system 
has five grades of severity of striatal involvement (111). Post-mortem autoradiographic studies 
of patients with HD at different stages have also suggested specific patterns of molecular 
degeneration based on the specific neurochemistry of the basal ganglia circuitry (112). 
Interestingly, the GABAA, cannabinoid CB1, dopamine D2 and adenosine A2a receptor density 
seems to be involved and decreased in early neuropathological grades of HD in the striatum 
whereas an increase of GABA-A receptors in globus pallidus pars externa (GPe) has been 
observed. The latter has been interpreted as a compensatory regulation of pallidal receptors in 
response to the ongoing denervation (113). Nowadays, MSNs are considered no more than one 
of the vulnerable neuronal populations. It is becoming more evident that the disease has a more 
multisystem character (114) with evidences of structural and functional abnormalities in the 
cerebral neo-and allocortex, selected thalamus nuclei, pallidum and different nuclei of the 
brainstem such as the substantia nigra, the pontine nuclei, reticulotegmental nucleus of the pons, 
superior and inferior olives (115, 116).  
 
1.3.2.2 Dopaminergic Imaging markers in HD 
Since the major pathological features in HD were traditionally related to the loss of MSNs in 
the striatum, different in vivo PET studies have been mainly focused on post-synaptic 
dopaminergic receptors. Reduction of dopamine D1 and D2 receptor availability were reported 
both in manifest and pre-manifest HDGECs.  
Multi receptors PET studies examining D1 receptors with [11C]SCH23390  and D2 receptors 
with [11C]raclopride  showed similar impairments of the two receptor systems in manifest  
(117, 118) and pre-manifest (119) HDGECs. Different PET studies performed with 
[11C]raclopride showed approximately 40-60 % loss of D2/3 receptors in the striatum of 
manifest HDGECs and approximately 10-50 % reduction in heterogeneous and small groups 
of pre-manifest HDGECs (117, 120-123) as compared to healthy control subjects. The 
variability, between studies, regarding the reduction of D2/3 receptors found in pre-manifest 
HDGECs might represent the consequence of a broad range of CAG repeats and the burden of 
pathology among the HDGECs examined. Conflicting results have also been obtained when 
dopamine D2/3 receptors availability was measured in extra-striatal areas (123-125). 
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Interestingly, the involvement of the post-synaptic system (D2/3) has been coupled with 
increased levels of microglial activation (126, 127). 
In vivo PET studies with pre-synaptic markers are limited. Reduction of striatal VMAT2 
binding have been reported in manifest HDGECs with the radioligand 
[11C]dihydrotetrabenazine with a more severe involvement in patients with the akinetic-rigid 
motor phenotype compared to the choreiform one. The estimated reduction of 25 % compared 
to healthy controls was estimated with partial volume effect correction (128).  In addition, in a 
small group of manifest HDGECs, 50 % reduction of DAT binding was described with 
[11C]beta-CIT-PET (117).  
 
1.3.2.3 Imaging phosphodiesterase 10 A in HD 
Among many interesting striatal targets, the intracellular Phosphodiesterase 10A (PDE10A) 
enzyme has recently gained a scientific attention for the key role in the regulation of striatal 
signaling and for the presence of suitable pharmaceutical compounds able to modulate it.  
PDE10A is highly expressed in MSNs of the striatum, at the confluence of the corticostriatal 
glutamatergic and the midbrain dopaminergic pathways, where it encodes the hydrolysis of both 
cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) (129). 
The resulting signaling cascades are likely to modulate the molecular signalling in the 
corticostriatothalamic circuit. In vivo imaging of PDE10A has been proposed as a suitable 
biomarker for the study of  molecular changes in the striatal MSNs. Recent PET imaging studies 
investigating the availability of PDE10A in HDGECs suggested a specific alteration of this 
protein along with the neurodegenerative process. There are several radioligands currently 
validated and used in vivo in clinical PET studies: [18F]JNJ42259152 (130), [18F]MNI-659 (131, 
132), [11C]IMA107 (133) and [11C]Lu AE92686 (134). Several studies have already been 
performed in manifest and pre-manifest HDGECs with the aim of examining the PDE10A 
enzyme. The work of Ahmad et al (130) was the first study showing a dramatic reduction (after 
PVE correction) of the enzyme in five manifest HDGECs compared to eleven non age matched 
healthy controls (70% in the caudate and 65% in the putamen). In the first cross sectional study 
employing a fully validated PDE10 radioligand [18F]MNI-659 (139), Russell et al showed an 
average reduction of PDE10A availability of 50% in three pre-manifest and eight manifest 
HDGECs compared to age-matched healthy controls (131). The same group has recently 
published a longitudinal study in which eight HDGECs (6 manifest and 2 pre-manifest) 
underwent two [18F]MNI-659 PET measurements one year apart. On average, the estimates of 
annual PDE10A loss was 16.6% in the caudate, 6.9% in the putamen and 5.8% in the globus 
  19 
pallidus (132). The outcome measures of this study were not corrected for PVE. More recently, 
using [11C]IMA107 PET, a group of twelve early pre-manifest HDGECs (approximately 25 
years before the predicted onset) showed respectively 25 and 33% reductions in the striatum and 
in the globus pallidus compared with age-matched healthy controls. At that “stage” in HDGECs, 
no evident volumetric changes were detected in the grey and white matter structures as result of 
a morphometric analysis (133). 
So far, the above mentioned studies have been focused only on the examination of the PDE10A 
enzyme, but have not examined how the loss of PDE10A is related to the loss of D2/3 receptors, 
a well-established striatal marker in HD. In addition, those PET studies have examined PDE10A 
only in some stages of the disease, but data across a wider range of disease, including both pre-
manifest and manifest stages are lacking. In this thesis, PDE10A has been examined in relation 
to D2/3 receptors in HDGECs studied at different stages of the disease. 

  21 
2 AIMS 
 
In this research plan, the overall aim was to utilize state-of-the-art molecular imaging with 
PET to evaluate in vivo molecular targets that might be useful to examine early changes in PD 
and HD patients.  
In paper I, we have been focused on examining the suitability of [18F]FE-PE2I as a tool for 
imaging the nigrostriatal pathway in PD.  
 
In paper II, the aim was to develop and validate a user independent approach tailored for the 
brainstem to quantify 5-HTT availability with [11C]MADAM, with the intention to apply the 
method in a cross sectional study examining early PD patients.    
 
In paper III, we wanted to apply the knowledge gained in the previous two studies to quantify 
in vivo the DAT availability in the substantia nigra, axons and striatal terminals in a larger cohort of 
early PD patients using [18F]FE-PE2I with a tailored template-based approach. 
 
In paper IV, we wanted to study the patterns of age related changes of two basal ganglia 
molecular targets (phosphodiesterase 10A and D2/3 receptors) in healthy volunteers in relation 
to structural changes.   
 
In paper V, the aim was to evaluate the availability of the phosphodiesterase 10A enzyme in 
basal ganglia across a broad disease spectrum of HDGECs (i.e., early pre-manifest, late pre-
manifest, stage 1, stage 2).  
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3 METHODOLOGICAL CONSIDERATION 
Materials and methods used in the present thesis are comprehensively described in each 
respective article or manuscript. In the following section some of the general and specific 
methodological aspects are presented and discussed.  
 
3.1 POSITRON EMISSION TOMOGRAPHY 
The PET measurements were performed using the High Resolution Research Tomograph 
(HRRT). The HRRT is a high resolution PET system (Siemens Molecular Imaging) designed for 
human brain and small animal imaging. The system consists of eight panel detectors with an 
octagonal array, which have two layers of Lutetium Oxyorthosilicate (LSO) (2.4 x 2.4 x 10) and 
LYSO crystals, a total number of crystals of 59,904 x 2 layers, an axial field of view of 24 cm, 
collecting 207 planes in the reconstructed images, with a slice thickness of 1.218 mm, and an 
average resolution of 2.3 mm full-width half-maximum (FWHM) in all directions. The 
resolution has been further improved by modeling the point spread function (i.e. the resolution 
of the system) in the reconstruction algorithm (Ordinary Poisson (OP)-3D-ordered subset 
expectation maximization (OSEM)) (135).  
 
3.2 MAGNETIC RESONANCE IMAGING 
MR examinations were acquired for several purposes:  
a. to rule out pathology or vascular changes.  
b. to obtain anatomical images for coregistration with PET images 
c. to define volumes of interest 
d. to retrieve normalization parameters to the standard space 
 
MRI images are generally coregistered to PET and segmented into gray matter (GM), white 
matter (WM), and cerebrospinal fluid (CSF) using SPM5 (Wellcome Department of Cognitive 
Neurology, University College London) of Freesurfer. MRI examinations of six subjects in 
paper II were collected with a 1.5-Tesla GE Signa Excite MR system (3DSPGR; 156 slices of 
1 mm thickness, FoV = 256 mm, matrix = 256 Å~ 256, resolution = 1 Å~ 1 Å~ 1 mm, TE = 5 
ms, TR = 20 ms). The rest of MR images for the subjects recruited for the study presented in 
paper I-II-III have been acquired with a GE MR750 3-Tesla system (IR-SPGR; 32 channel 
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coil, 176 slices of 1 mm thickness, FoV = 256 mm, matrix = 256×256, resolution = 1×1×1 
mm, TI = 450 ms, TE = 3.18, TR = 8.16). MR images for the subjects recruited for the study 
presented in paper IV-V were collected with a GE MR750 3 Tesla system (IR-SPGR; 8 channel 
coil, 176 slices of 1 mm thickness, FoV=256 mm, matrix 256×256, Resolution 1×1×1 mm. 
TI=450 ms, TE=3.18, TR =8.16). 
   
3.3 IN VITRO AUTORADIOGRAPHY STUDIES 
Autoradiography is an in vitro technique used to produce high-resolution images of the 2D 
distribution of a radioactive substance. In relation to PET studies the autoradiography 
technique might be helpful to verify or validate a given molecular target of interest (i.e. 
histochemical validation of in vivo imaging target) or to obtain detailed maps of 
receptor/transporter/enzyme distribution (i.e. whole hemisphere autoradiography). The 
principle of in vitro autoradiography studies is to incubate tissue sections with a radiolabelled 
compound and to measure the concentration of radioactivity in the tissue using a 
phosphoimager. In our setting, autoradiography studies were carried out essentially as 
described earlier in previous publications (136). In brief, post mortem whole hemispheres 
were removed, frozen, and cryosectioned into 100 µm-thick coronal sections using a heavy-
duty cryomicrotome. For the examination conducted in paper II sagittal and axial section of 
the brainstem were used. In the experiment all sections were incubated at room temperature 
with the radioligand for the serotonin transporter [3H]MADAM (137). Specific binding was 
measured after blocking with a selective 5-HTT inhibitor (fluoxetine). 
 
3.4 KINETIC MODELING AND OUTCOME MEASURES 
In paper I, all the PET studies were analyzed with the simplified reference tissue model (SRTM) 
and the Logan graphical analysis, using the cerebellum as reference region and the software 
PMOD. As result of the kinetic models, estimates of regional binding potential relative to the 
non-displaceable compartment (BPND) were selected as the study outcome measure.  
In paper I, II and III, parametric images of BPND (voxel-based maps) were obtained with the 
software WAPI, using Logan graphical analysis and the cerebellum as a reference region.   
In paper 4 and 5, the kinetic model of choice to estimate the outcome measure for [18F]MNI-659 
was the two-tissue compartment model (2TCM) including the arterial input function. This model 
was used to derive indirectly BPND (VT-VND/1). VT represents the total distribution volume in the 
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target regions (striatum and globus pallidus) and VND represents distribution volume in the non-
displaceable compartment. The choice of 2TCM was based on a preliminary evaluation 
performed in 15 healthy subjects. One-Tissue compartment model (1TCM) and SRTM were not 
optimal in describing the time activity curves of [18F]MNI-659 because of a number of fitting 
failures or poor model fits. 2TCM was the method that consistently generated a better fitting for 
all the ROIs except for the cerebellum, in all subjects. A straightforward solution to compensate 
the fitting imprecision in the cerebellum was to include the fraction of the blood volume as a 
fifth parameter. Visual inspection of parametric images of [18F]MNI-659 provided evidence of 
high binding of the radioligand in the venous sinuses in the brain. PDE10A is present in vascular 
smooth muscle cells (138). Therefore, the binding observed in the venous sinuses could be 
related to the presence of PDE10A in the vasculature. In a low binding region as the cerebellum, 
the vascular binding of [18F]MNI-659 is not negligible and might contribute to the signal 
measured in this region. The discrepancies observed in the performance of SRTM compared to 
the already published studies with [18F]MNI-659 (131,132, 139) might be related to different 
PET system employed in those studies. Differences in the sensitivity to low counting statistics of 
the HRRT PET system may have influenced the reported differences in fitting performance in 
the cerebellum. In paper IV-V, the kinetic model of choice to retrieve the outcome measure 
BPND for [11C]-raclopride was SRTM.  
 
3.5 PARTIAL VOLUME EFFECT AND CORRECTION 
In paper IV and V, the outcome measures presented were obtained from regional time-activity 
curves corrected for Partial Volume Effect (PVE). PVE is an phenomenon related to the 
limited resolution of the PET system (140). Because of PVE, the radioactivity concentration in 
different regions is under or over estimated due to “spill-over” of measured radioactivity 
between neighboring regions. This effect is more evident when the contours of the regions of 
interest are delimited by other regions or tissues with different target availability such as it is 
present in the basal ganglia. This effect is also enhanced by the presence of significant brain 
atrophy resulting in a predictable underestimation of  target availiability (i.e. striatal atrophy in 
the striatum in HD). The application of PVE correction (PVEc) methods is thus important, 
despite the fact that such methods can be associated with possible biases due to noise 
amplification. Limitations related to the intrinsic presence of tissue in-homogeneities and 
susceptibility to suboptimal MRI and PET preprocessing (segmentation and co-registration) 
(141) should also be considered. The PVEc method used in paper IV and V is an 
implementation of the Rousset method that is based on the estimation of a geometric transfer 
  25 
matrix (GTM) to describe and thus correct for signal contamination occurring between 
neighboring ROIs.  
The actual implementation in our setting includes the effective resolution and point spread 
function of the HRRT PET system and the anatomical details and precisions of the ROIs 
boundaries provided by the MRI preprocessing with Freesurfer. The use of high resolution 
PET imaging and the application of PVEc to the PET data acquired in this thesis were aimed 
to achieve high accuracy of the quantification of molecular target in the striatum and small 
brain regions (135) (Figure 6).  
 
Figure 6: Representative average [18F]MNI-659 (left) and [11C]raclopride (right) images before and 
after partial volume correction (PVEc). Courtesy of Martin Schain.  
3.6 TAILORED TEMPLATE-BASED ANALYSIS USING PARAMETRIC IMAGES 
In paper II and III, 3T-MR images and HRRT-PET parametric images were used to generate a 
template of [11C]MADAM and [18F]FE-PE2I binding to 5-HTT and DAT. An automated 
brainstem weighted co-registration method developed for fMRI imaging analysis (142) was used 
to obtain an accurate normalization of individual structural 3T-MR images and HRRT-PET 
parametric images into the standard Montreal Neurologic Institute (MNI) space. The 
normalization was performed with a two-step approach based on two consecutive affine linear 
transformations applied on the individual T1-weighted MRI scans using FLIRT, a linear Image 
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Registration Tool from FMRIB's Software Library (FSL, Oxford) (143). An extended MNI-152 
brainstem mask that included the third ventricle, part of lateral ventricle and part of the thalamus 
was used as a reference volume, to weigh the second full affine transformation. The parameters 
obtained with the concatenation of the two transformations were subsequently applied to ten 
individual parametric PET image (after co-registration to MR space) to create a set of ten 
parametric images in the MNI standard space. Those ten parametric images (all in the standard 
MNI space) were subsequently averaged in order to obtain a representative PET template of 5-
HTT and DAT binding (Figure 7). Normalization parameters were obtained also from subjects 
not involved in the generation of the template.  
 
Figure 7. Images of the two PET templates for 5-HTT and DAT. Axial, coronal and sagittal. Color bars 
specify Binding potential (BPND) values of the brain PET images.  
In Paper II, template-based volumes of interest (VOIs) were defined on the PET template using a 
previously published threshold-based VOI-delineation method (26). In short, the delineation of 
each VOI was initiated with the definition of a bounding box that enclosed the anatomical 
structure in the co-registered MR images. The bounding box was then reduced, so that only 
voxels displaying higher BPND values than a threshold were included in the final VOI. The 
threshold used for the erosion of the bounding box was set to include the relevant binding in 
each brain region and to provide volumes of each anatomical structure in agreement with those 
found in the literature (26).  
The VOIs generated on the PET template included the ventral midbrain, superior colliculi, 
dorsal raphe, median raphe and the caudal raphe.  
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In Paper III, VOIs were manually delineated on the DAT template using anatomical and DAT 
binding patterns by overlaying the two modalities (MR-MNI template and HRes DAT template) 
using the Human Brain Atlas software. The VOIs generated on the PET template included the 
caudate, putamen, ventral striatum and substantia nigra. Noteworthy the template enabled the 
visualization of DAT binding of [18F]FE-PE2I along different axonal projections generated from 
the substantia nigra. For both papers II and III, all template-based VOIs were then transformed 
and projected to the individual space (using the inverted normalization parameters) and applied 
upon each subject’s parametric image to estimate the average regional BPND values. 
  
3.7 RECRUITMENT AND CHARACTERISTICS OF PARKINSON AND 
HUNTINGTON’S DISEASE PATIENTS 
In paper I and III PD patients were recruited at the movement disorders clinic of the Karolinska 
University Hospital in Huddinge and through the Swedish Parkinson patient association in 
Stockholm (Parkinsonförbundet). Patients satisfied the clinical diagnosis of PD according to the 
U.K. Parkinson Disease Society brain bank criteria (57). Patients were evaluated while in ”on” 
state with the Hoehn and Yahr (H&Y) staging and using the motor part of the Unified 
Parkinson’s Disease Rating Scale (UPDRS-m) (Table 1).  
 
Table 1. Demographic and clinical data of Parkinson´s patients. Key: MMSE, Mini-Mental State 
Examination; F, female; M, male; UPDRS, Unified Parkinson’s Disease Rating Scale; Side, the clinical 
most affected side; LED; Levo-Dopa Equivalents. The first ten PD patients were included also in paper 
I.  All PET measurements were performed in ”off” state.  
 28 
 
In paper V, HDGECs were also participating to REGISTRY or ENROLL-HD studies and were 
pre screened for possible eligibility. HDGECs were recruited and screened in six clinical sites in 
Sweden, Denmark, Norway and the Netherlands.  
The stratification of HDGECs was based on the number of CAG repeats, age of the subject and 
by specific clinical outcome measures generated with validated clinical assessments tools such 
as the Total Functional Capacity (TFC) score and Total Motor Score of the Unified 
Huntington’s Disease Rating Scale (UHDRS) (144).  The functional section of the UHDRS 
(TFC) provides an assessment of HDGECs manifest patients at a functional level and it codifies 
patients in five stages. Different functionalities are evaluated in the domains of workplace, 
finances, domestic chores, activities of daily living and requirements for unskilled or skilled 
care. The motor section of the UHDRS (TMS) is a clinical rating scale that evaluates manifest 
HDGECs in the motor domain (i.e. eye movements, amount of 
chorea/dystonia/bradykinesia/dysartria, gait and balance).  
REGISTRY and ENROLL-HD are studies collecting prospective data on the phenotypical 
characteristics of HDGECs and individuals that are part of an HD family. 
 In paper V HDGECs were subdivided in different stages of the disease (early pre-manifest, 
early pre-manifest, stage 1 and stage 2) (Table 2).  
 
Table 2. Clinical characteristics of Huntington Disease Gene Expansion Carriers (HDGECs) in the 
different stages.  Key: F, female; M, male; DBS, Disease burden score: age × (CAG length–35·5); 
mUHDRS-TMS, unified Huntington’s disease rating scales- total motor score.  
  
  29 
4 RESULTS AND REFLECTIONS 
 
4.1 PAPER I 
4.1.1 Evaluation of [18F]FE-PE2I as radioligand for DAT imaging in vivo in PD 
patients and in healthy controls.  
The study included 10 early PD patients (9M/1F, 60±9y, Hoehn&Yahr: 1-2; Unified 
Parkinson’s Disease Rating Scale motor: 18.9±6.7) and 10 controls (9M/1F, 60±7y). Regions 
of interest for caudate, putamen, ventral striatum, substantia nigra and cerebellum were drawn 
on co-registered magnetic resonance images. The outcome measures was the binding 
potential (BPND) estimated with the simplified reference tissue model (SRTM) and the Logan 
graphical analysis (LoganRef), using the cerebellum as reference region. Time stability of 
BPND was examined to define the shortest acquisition protocol for quantitative studies. The 
wavelet-aided parametric imaging method was used to obtain high-resolution BPND images. 
Venous blood was drawn to compare protein binding, parent fraction and radiometabolite 
composition in PD patients and healthy controls. The results showed that [18F]FE-PE2I has a 
similar metabolism in PD patients and control subjects and that cerebellum is a suitable 
reference region. Accurate quantification could be achieved using 66 minutes of PET data. 
DAT availability in PD patients was significantly lower than in controls, by 69% in the 
putamen, 31% in the caudate, 32 % in the ventral striatum and 33% in the substantia nigra. 
These findings suggested that [18F]FE-PE2I is a suitable radioligand for DAT quantification 
in both striatum and substantia nigra in PD patients. The quantification can be performed 
non-invasively using the cerebellum as reference region. The suitable kinetic properties 
permit also to use simplified acquisition protocols. 
 
4.1.1.1 Reflections 
The suitability of [18F]FE-PE2I as an imaging tool to reliably measure DAT availability in 
striatal and extrastriatal regions in PD patients was based on the following considerations 
partly from previous studies (85, 145, 146) (a-b-c-d) and from the results obtained with this 
study (d-e-f-g):  
a. [18F]FE-PE2I is labelled with 18F, therefore the radioligand could be used even in 
imaging facilities without a cyclotron and a radiochemistry unit.  
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b. [18F]FE-PE2I has adequate affinity (Ki=12 nM) and selectivity for the DAT (>80-fold 
higher affinity to DAT than to 5-HTT). These properties enable to image the DAT 
also in the substantia nigra. 
c. Peak equilibrium of [18F]FE-PE2I in the striatum and the substantia nigra is reached 
between 20 and 40 min, assuring accurate quantification of DAT in both regions.  
d. Cerebellum is a suitable reference region, enabling the quantification in a non-
invasive way.  
e. The fraction of parent and radiolabelled metabolites of [18F]FE-PE2I did not differ 
significantly between PD patients and controls. The fraction of the radiolabelled 
metabolite of [18F]FE-PE2I that might enter the brain (hydroxy-methyl analog) was 
negligible (<2%) and should not affect the quantification. There is therefore no need 
to collect blood samples and perform metabolite analysis in future PET studies. 
f. The accuracy of quantification can be achieved using  ̴ 66 minutes of PET 
measurements in the caudate, putamen, ventral striatum and substantia nigra.  
g.  [18F]FE-PE2I can be analysed with non-invasive and simplified imaging protocols 
for clinical studies in PD studies. 
 
From a clinical perspective the possibility to study with the same radioligand the availability 
of DAT at pre-synaptic level (striatal terminals) and where the dopaminergic projections are 
generated (cell bodies of dopaminergic neuron in the substantia nigra) represent a unique 
opportunity for future application in clinical studies of PD and atypical parkinsonisms (see 
section 5.1.1.1).  
From a learning perspective this study gave me the opportunity to understand the principles 
of PET data analysis and kinetic modeling. The challenges of this study introduced me to the 
complexity of the essential infrastructure and expertise needed for the collection and 
gathering of all relevant data (i.e. clinical outcome measures). A considered amount of time 
was spent to adjust and adapt the methodological skills connected to the study program and to 
the acquisition and quantification of PET data. I’m grateful to have had the opportunity to 
work with [18F]FE-PE2I which is a radioligand with optimal image and kinetic properties. 
These results have been achieved after approximately 10 years of progressive validation and 
development. 
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4.2 PAPER II 
4.2.1 Quantification of 5-HTT binding in small nuclei of the brainstem: a 
validation of a template based approach.  
The template-based analysis was performed on 16 healthy subjects (14M/2F, 21-67 y) that 
were examined with [11C]MADAM using the HRRT system. Individual BPND parametric 
images of 5-HTT availability were generated for each subject. VOIs were defined with a 
template-based method described in the previous section and then transformed and applied to 
each subject’s parametric image to estimate regional BPND values. The VOIs of this study 
were the ventral midbrain, superior colliculi and the dorsal-median-caudal raphe. To validate 
this user-independent approach, regional template-based BPND values were compared to 
subject-based BPND values obtained using a threshold-based ROI-delineation method at 
individual level (23) and with the specific binding obtained with post-mortem 
autoradiography studies with [3H]MADAM in sections that included the above mentioned 
regions.  
The distribution of template-based BPND values was consistent with the pattern of specific 
binding previously obtained from previous post-mortem autoradiography for all subjects with 
a relative order of BPND as follows: dorsal raphe > median raphe > superior colliculi > 
ventral midbrain > caudal raphe (Figure 8).  
 
Figure 8. Distribution of SERT binding sites in brainstem nuclei: PET and post mortem 
autoradiography findings (left and right panel). Sagittal plane sections of 5-HTT distribution patterns 
obtained with PET (representative parametric images) with [11C]MADAM and with autoradiography 
studies with [3H]MADAM. 
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The values obtained with the template based approach were systematically lower than those 
obtained using individually defined ROIs, although a significant correlation between BPND 
obtained with the two methods was observed (r2=0.83). In vitro post-mortem distribution of 
[3H]MADAM measured with autoradiography confirmed high specific binding in the dorsal 
and median raphe followed by superior collicoli and caudal raphe and intermediate values in 
the ventral midbrain striatum and amygdala. There was a relationship (r2=0.62) with the 
template-based BPND in the comparable regions.  
 
4.2.1.1 Reflections 
The proposed template-based method together with the high resolution PET imaging 
represent a relevant development for the quantification of 5-HTT in the brainstem nuclei. 
Indeed, to the best of our knowledge, literature data for the entire set of VOIs quantified in 
this study are not available except for the dorsal raphe. The current golden standard for the 
definition of brain stem regions (i.e. dorsal raphe) is the manual definition of the region on 
MRI images. This approach has inherent difficulties that might lead to an erroneous 
definition and localisation of the structures (147). The method proposed in this study 
provides a more robust quantification of the 5-HTT in the brainstem. The possibility to 
quantify the different portions of the raphe nuclei (dorsal-median-and caudal) is relevant for 
the study of the neurobiology of the serotonin system (148). There are indeed several CNS-
disorders in which serotonin neurons in the brainstem might be affected. In this respect, the 
greatest benefit of using a template-based approach for definition of VOIs is that the 
assumption regarding the volume of the structure is only introduced at a group level. The 
template-based approach is thereby less prone to suboptimal sampling attributable to the 
highly variable brainstem anatomy in term of dimensions and orientation, to the intrinsic 
variability in the localisation of the raphe nuclei complex and to changes of 5-HTT 
availability due to aging processes or neuropathological modifications.  
From a learning perspective this paper helped me in the development of skills related to the 
analysis of PET data in a less conventional way. In that respect, it was the first experience 
with generation of a functional template for PET analysis. This study allowed me to deep 
the understanding of the anatomy and functions of small monoaminergic nuclei enriched in 
the brainstem and their relevance in studying CNS disorders in which an involvement of 
those structures it has been already established. On the other hand, it made me aware of the 
actual difficulties and challenges of the neuroimaging communities in studying, in vivo, 
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some of the presented brainstem structures. This study introduced me to the use of post-
mortem autoradiography studies that turned to be important in the development of 
competences and knowledge that are gained by the comparisons between in vitro post- 
mortem applications and in vivo PET studies.  
 
4.3 PAPER III 
4.3.1 DAT availability in the substantia nigra, axons and striatal terminals in 
early PD patients 
As reported in study 1, [18F]FE-PE2I is a radioligand with image properties that enables the 
visualization and the reliable quantification of DAT availability also in the substantia nigra. 
By generating a DAT template as described in the section 3.6 we were able to clearly 
visualize the presence of binding located even along efferent fibers from the substantia nigra 
(Figure 10). Template-based ROIs were anatomically delineated (manually) on striatal 
(caudate, putamen and ventral striatum) and extrastriatal (substantia nigra) regions and along 
nigro-striatal (NST), nigro-pallidal (NPT), nigro-thalamic tracts (NTT).  
 
 
Figure 10. Anatomical study of DAT binding in dopaminergic axonal projections. A. Coronal 
section, at striatal level, of DAT template overlaid on MRI MNI template. B. Striatal 3D rendering 
obtained from DAT template of [18F]FE-PE2I. C-D-E. Coronal sections at mesencephalic and 
dienchephalic level displaying the DAT binding in different dopaminergic projections. 
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With the presented methodology it became feasible to image the DAT availability in the 
entire dopaminergic nigro-striatal system and apply this analysis to PD patients. In early PD 
patients we found significantly lower BPND values compared to healthy controls in the 
putamen (PD: 1.33±0.7 vs HC: 4.40±0.6), caudate (PD: 2.42±0.8 vs HC: 4.03±0.6), ventral 
striatum (PD: 2.21±0.7 vs HC: 3.45±0.7) and substantia nigra (PD: 0.58±0.1 vs HC: 
0.84±0.1) (p<0.001). Average BPND values in the tracts were much lower than in the 
substantia nigra without a significant difference between the two groups (PD: 0.42±0.1, HC: 
0.47±0.1). The largest differences in DAT availability in the tracts between PD patients and 
healthy controls were found in the nigro-pallidal tract (PD: 0.32±0.1, HC: 0.44±0.1).  
This difference did not reach statistical significance after Bonferroni´s correction (p=0.07).   
4.3.1.1 Reflections 
The findings of this study demonstrated in vivo for the first time that in early PD patients 
there is a prominent reduction of DAT availability at pre-synaptic terminal level 
(putamen>caudate>ventral striatum) and to a less extent in the substantia nigra where the 
cell bodies are located. Moreover, the DAT binding measured along the dopaminergic 
projections seem to be less affected in early PD patients without clear distinctions 
compared to healthy control subjects.  
The described molecular pattern partially confirms some preclinical and post-mortem 
evidences that support the hypothesis of a primary involvement of  synapses and pre-
terminal axons in the neurodegenerative process of PD followed by a “retrograde” 
degeneration of cell bodies (60,61,149). Following this hypothesis one might expect an 
involvement of axons preceding that of cell bodies in the substantia nigra. The findings of 
this study showed that DAT along the axons is preserved to a similar or larger extent than 
the DAT in the cell bodies. The relative preservation along nigro-striatal projections might 
be explained also with a compensatory up-regulation of the DAT along the axons in 
presence of severe pre-terminal degeneration (150).  
From a learning perspective, this paper was very important for me because I was 
independently responsible for most of the methodological and organizational aspects of the 
study. In addition, through a serendipitous discovery of the presence of [18F]FE-PE2I 
binding along the nigro-striatal projections, I was able to acquire additional knowledge on 
the anatomical and topographical distribution of the nigro-striatal tracts across species.   
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4.4 PAPER IV 
4.4.1 Age related reduction of PDE10A availability in the basal ganglia 
The aim of this study was to evaluate the availability of PDE10A measured with the PET 
radioligand [18F]MNI-659 in relation to age-related and/or volumetric changes. These 
changes along with the limited resolution of PET might lead to inaccurate quantitative 
measures of target availability. In order to improve the accuracy of the quantification, in the 
present study the effect of age on PDE10A availability and on the volumes in the basal 
ganglia was performed using the HRRT system, high resolution MRI and PVE correction 
(methodology described in section 3.5). D2/3 receptor imaging was used as supplementary 
reference basal ganglia PET biomarker. This evaluation was conducted in 40 healthy control 
subjects (age 44±11, age range 27-69). The PET outcome measure was BPND, estimated 
using 2TCM for [18F]MNI-659 (PDE10A) (described in section 3.4) and SRTM for 
[11C]raclopride (D2/3 receptors), using the cerebellum as reference region. Time activity 
curves were corrected for PVEc. Age-related changes of PET and MRI outcome measures 
were examined using multiple linear regression analysis also including gender as covariate. 
The analysis showed the presence of a significant effect of age on the availability of PDE10A 
in the striatum with a decline rate of 8% per decade. A significant reduction of striatal 
structural volume was also detected (Figure 11).  
 
Figure 11. Correlation plots showing the relationship between age and PDE10A, Dopamine D2/3 
Receptors and volumes in the striatum and globus pallidus separated for gender. Displayed partial 
correlation coefficients (ß values) for the independent variable age and significance level (p) referred 
to the multiple regression analysis that included gender as covariate. * =p < 0.008 (significance after 
Bonferroni´s correction). 
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The availability of PDE10A enzyme and D2/3 receptors were correlated in the caudate and 
putamen. However, a different distribution was observed in the globus pallidus and the 
nucleus accumbens. The availability of PDE10A was much higher than that of D2/3 receptors 
in the globus pallidus. In the nucleus accumbens, negligible binding of [18F]MNI-659 was 
observed, indicating negligible density of PDE10A, in agreement with in vitro findings 
observed in post-mortem autoradiography. As an additional finding, an effect of gender on 
PDE10A availability was also observed in the striatum (p=0.02). 
 
4.4.1.1 Reflections 
These results indicate that aging is associated with a considerable physiological reduction of 
the availability of PDE10A enzyme in the striatum. In the striatum, PDE10A availability 
showed a significant age-related decline that was larger compared to age-related decline of 
volumes measured with MRI and to the age-related decline of D2/3 receptors availability. In 
the globus pallidus, a less pronounced decline of PDE10A availability was observed, whereas 
D2/3 receptors availability and volumes seemed to be rather stable with aging. As a result of 
this analysis it appears clear that the combination of high-resolution PET and PVEc 
represents an advantage regarding the accuracy of PET measurements of the two molecular 
targets, PDE10A enzyme and D2/3 receptors. In addition, age-matching (and for PDE10A also 
gender-matching) is extremely relevant in clinical PET studies which aim to examine the 
contribution of volume/neuronal loss (determined by age or pathology) in relation to the 
PDE10A and D2/3 receptors. From a learning perspective with this study I challenged my 
problem solving and analytical skills with further improvement in relation to PET analysis 
(i.e. challenges of the kinetic analysis of [18F]MNI-659 together with the application and 
validation of the PVCc of PET data). This paper introduced me to the analysis of MRI 
structural images in relation to PET outcome measures which I found stimulating and 
informative.  
The work performed for Study IV was the methodological foundation for the clinical 
application performed in HDGECs in study V. 
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4.5 PAPER V 
4.5.1 Examination of PDE10A availability across a broad spectrum of HD 
stages 
The objective of this study was to examine the loss of PDE10A enzyme across a broad 
spectrum of HD stages. The study was cross-sectional with an adaptive design, examining 
HDGECs at different stages of the disease (early pre-manifest, late pre-manifest, stage 1 and 
stage 2) in comparison with control subjects matched by age and gender. Data were collected 
between April 4, 2013 and May 31, 2016. We obtained [18F]MNI-659 and [11C]raclopride 
PET data and MRI volumetric measurements for the following regions of interest: caudate, 
putamen and globus pallidus. PET data were analyzed as presented in study IV. Molecular 
and structural data were obtained from eighty-nine participants (44 HDGECs/45 controls) 
and included in the final analysis.  
In each region of interest, significantly lower BPND were detected in HDGECs compared to 
control values. A preservation of PDE10A and D2/3 receptors was observed in HDGECs in 
the early pre-manifest stage. A differential pattern of PDE10A and D2/3 receptor loss in 
striatum and globus pallidus of HDGECs was observed. At manifest stages (Stage 1) 
PDE10A loss was larger than that of D2/3 receptor. A plateau of PDE10A and D2/3 receptors 
loss was reached from stage 1 to stage 2 (Figure 12). 
 Both PDE10A and D2/3 availabilities were predictive of disease burden score. 
 
Figure 12. Percentage differences between HDGECs and HCs in the caudate (A) and putamen (B) 
for PDE10A enzyme (red), D2/3 receptors (green), and volumes (blue) in the defined pre-manifest and 
manifest stages. Percentage differences were calculated for each HDGECs sub-group relative to its 
age- and gender-matched controls subgroup. 
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4.5.1.1 Reflections 
The first interesting finding of this study was that in the early pre-manifest HDGECs group 
(see table 2 in section 3.7) PDE10A, D2/3 receptors and structural volumes did not differ from 
those measured in healthy controls. Between such early pre-manifest stage and the late pre-
manifest stage an apparent molecular and structural phenotypic conversion begins and this 
might be relevant for the application of potential neuroprotective treatments. Another novel 
and interesting findings is that the transition between late pre-manifest and stage 1 appears to 
show a "turning point". In particular, it seems that during this late pre-manifest stage the 
decrease of PDE10A occurs at a larger rate as compared with D2/3 receptors and striatal 
volumes and this is relevant because potentially indicates the suitability of PDE10A imaging 
as a sensitive biomarker of disease progression. Finally, when HDGECs reach stage 1-2, the 
decrease of PDE10A, D2/3 receptors and volumes seems to be so pronounced that probably an 
intervention at this stage might not effectively modify the disease course. 
There are some considerations to be done regarding PDE10A imaging and the radioligand 
[18F]MNI-659 since the outcome measures obtained were highly variable between individuals 
(healthy controls and HDGECs). Part of the variability might be related to some extent to the 
characteristics of the radioligand but also linked to a functional intrinsic molecular inter-
individual variability of the target per se. PDE10A enzyme is intracellular and can undergo 
diﬀerent compartimentalization in the cytoplasma and Golgi complex or exists in diﬀerent 
activation states (active or hyperactive). Therefore, the binding of [18F]MNI-659 might be 
inﬂuenced by diﬀerences in the intra-cellular environment or activation state of the enzyme 
across subjects, partly contributing to the observed variability of the measured PDE10A 
availability.  
From a learning perspective this study introduced me to the field of Huntington’s disease 
and the efforts employed in this study by so many experts was a teaching experience about 
professionalism. The study has accompanied me during almost the entire PhD (between 
2013-2016) period so in a way the results came along together with increased knowledge of 
the disease and improved personal skills. From an individual perspective this study allowed 
me to know personally a broad number of individuals affected by the mutation for the HD 
gene and this was an important motivation to carry on the efforts to successfully complete the 
clinical study.  
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5 FUTURE PERSPECTIVES 
5.1.1.1 The use [18F]FE-PE2I as potential clinical biomarker 
Early differential diagnosis of PD is challenging with a misdiagnosis rate as high as 20–30 %.  
Parkinsonism as defined by UK brain bank criteria is not sufficient to assign a “diagnostic 
label” of sporadic PD or to recognize other atypical parkinsonian conditions such as 
progressive supranuclear palsy (PSP) multiple system atrophy (MSA), corticobasal 
degeneration (CBD) and Lewy-body dementia. Misdiagnosis is so common because of the 
absence of a lack of reliable biological biomarkers. [18F]FE-PE2I might represent a 
potentially valuable tool that can help increase diagnostic specificity for dopamine-deficient 
parkinsonian syndromes and rationalize management decisions at initial stages of disease 
since it has demonstrated to be capable to evaluate the DAT availability in altered nigral 
structure and striatal dopamine terminals.  
Different patterns of degeneration may characterize the mentioned different conditions in 
regard of the nigral involvement. It has already been shown that the degree of cell loss in 
patients with PSP with gaze palsy compared to patients without gaze palsy is different with 
40 % greater loss of neurons in the substantia nigra pars reticulata (SNr) (151). Moreover 
[18F]FE-PE2I can become a tool to monitor disease progression or the efficacy of 
pharmacological intervention. Longitudinal studies are needed in order to understand the 
ability of the radioligand to detect the amount of DAT changes that occurred in PD at 
different stages in 1-2 years and to evaluate inter-individual differences in disease 
progression.   
5.1.1.2 Phosphodiesterase 10 A imaging as a pharmacodynamic biomarker 
The examination in vivo of PD10A as target has demonstrated interesting potential as a 
disease biomarker in HD. Based on the results of the studies revised in section 1.3.2.2 and the 
study presented in paper V the measurement of PDE10A availability can be advocated, at the 
moment, as a suitable molecular imaging marker in future HD trials.  
For the application of PDE10 imaging in future HD trials it is necessary to apply this tool into 
large longitudinal studies in order to understand the sensitivity of the radioligand in detection 
of changes and to evaluate inter-individual differences in the disease progression.  Moreover, 
this molecular target might be used as a tool for patient’s “enrichment” so that only patients 
with a certain PDEA level may entry in a given clinical trial. The findings of this study might 
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suggest that late pre-manifest HDGECs are probably the main target group where the effect 
of neuroprotective interventions or disease modifying therapies could be expected.  
Finally it would be interesting to study the exact role and function of PDE10 in the regulation 
of striatal signaling (i.e. relations with other phosfodiesterase (PDE4), with other 
monoaminergic systems or neurotransmitters such as GABA and Glutamate). 
5.1.1.3 Future directions of the field in the study of neurodegenerative disorders  
Regarding potential directions of the field outside the project and the technologies presented 
in this thesis, I think that there other potential relevant questions that will be soon or later 
answered by dedicated PET imaging studies. 
In the next future, the imaging community may face an era in which dedicated biomarkers of 
protein aggregation (α-syn or m-HTT) may become available. Those imaging probes might 
shed some lights in prominent pathological features and might allow a precise monitoring of 
the effects of therapeutics targeting the protein misfolding process.  
Moreover, the availability of dedicated radioligand for α-syn, beta amyloid and tau might be 
relevant to start to evaluate the complex interplay between misfolding proteins in different 
neurodegenerative disorders (i.e. dementias and parkinsonisms).  
In the same desirable future another topic of interest would be the evaluation of the 
relationships between the progressive pathologic protein accumulations (i.e. lewy bodies, m-
HTT) and different neuroinflammatory aspects. 
Finally, I am in favor of using PET imaging as a tool to stratify patients affected by 
neurodegenerative disorders that, without exceptions, in the clinical practice show a marked 
inter-individual variability.  
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